According to Gilead Sciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.4784. At the end of 2022 the company had a P/E ratio of 23.4.
Year | P/E ratio | Change |
---|---|---|
2022 | 23.4 | 59.47% |
2021 | 14.7 | -97.48% |
2020 | 583 | 3701.51% |
2019 | 15.3 | 2.96% |
2018 | 14.9 | -26.45% |
2017 | 20.2 | 184.87% |
2016 | 7.10 | -13.23% |
2015 | 8.19 | -30.86% |
2014 | 11.8 | -68.31% |
2013 | 37.4 | 73.46% |
2012 | 21.5 | 91.56% |
2011 | 11.2 | 4.87% |
2010 | 10.7 | -27.65% |
2009 | 14.8 | -37.99% |
2008 | 23.9 | -9.63% |
2007 | 26.4 | -206.29% |
2006 | -24.9 | -184.23% |
2005 | 29.5 | -12.22% |
2004 | 33.6 | -122.51% |
2003 | -149 | -262.62% |
2002 | 91.9 | -20.3% |
2001 | 115 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 10.3 | -28.68% | ๐บ๐ธ USA |
Pfizer PFE | 14.9 | 2.67% | ๐บ๐ธ USA |
AbbVie ABBV | 45.3 | 212.55% | ๐บ๐ธ USA |
Eli Lilly LLY | 163 | 1,023.72% | ๐บ๐ธ USA |
Amgen AMGN | 21.1 | 45.70% | ๐บ๐ธ USA |
Biogen BIIB | 12.7 | -12.51% | ๐บ๐ธ USA |
Illumina ILMN | -4.10 | -128.35% | ๐บ๐ธ USA |
Vertex Pharmaceuticals VRTX | 36.6 | 152.76% | ๐บ๐ธ USA |
Merck MRK | 71.0 | 390.50% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.